The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorHelal T.E.A.
dc.contributor.authorRadwan N.A.
dc.contributor.authorMahmoud H.A.
dc.contributor.authorZaki A.M.E.
dc.contributor.authorAhmed N.S.
dc.contributor.authorWahib A.A.A.
dc.contributor.authorAref A.M.
dc.contributor.otherDepartment of Pathology
dc.contributor.otherFaculty of Medicine
dc.contributor.otherAin Shams University
dc.contributor.otherRamses Street- New Faculty Bldg. -5th floor
dc.contributor.otherP.O. # 11566
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Internal Medicine
dc.contributor.otherFaculty of Medicine
dc.contributor.otherAl-Azhar University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Faculty of Biotechnology
dc.contributor.otherOctober University for Modern Sciences and Arts (MSA)
dc.contributor.otherGiza
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:40:40Z
dc.date.available2020-01-09T20:40:40Z
dc.date.issued2019
dc.descriptionScopus
dc.description.abstractBackground: Interferon therapy is used as a line of treatment of chronic hepatitis C virus (HCV) in several areas of the world including Egypt. Objective: Our aim was to investigate the value of hepatic progenitor cells (HPCs) in predicting response of patients with chronic HCV, genotype 4 to pegylated interferon (PEGIFN) plus ribavirin (RBV) therapy. Methods: Pre-treatment liver biopsies obtained from 110 patients with chronic HCV, genotype 4 were examined immunohistochemically for HPCs using cytokeratin19. The mean number of HPCs as ductular reaction (DR) and as isolated progenitor cells (IPCs) was counted in each case. The patients were classified into: those with sustained virological response (SVR) and those who did not achieve SVR. The results were compared between the two groups. Also, the relationships between HPCs and other clinico-pathologic variables were estimated using multivariate analysis. Results: The mean number of HPCs was the only independent predictor of therapeutic response, being significantly higher in non-responders (P = 0 for DR and P = 0.03 for IPCs). On the other hand, fibrosis stage and steatosis were the only independent factors which showed a significant direct association with the mean number of HPCs in the form of DR and IPCs (P = 0 for each). Conclusion: The number of HPCs provides prognostic information in chronic HCV since it is significantly associated with stage of fibrosis. More importantly, it can be used as a marker to predict response of patients with chronic HCV to PEGIFN plus RBV therapy. � 2019 Helal et al. Licensee African Health Sciences.en_US
dc.identifier.doihttps://doi.org/10.4314/ahs.v19i1.14
dc.identifier.doiPubMedID31148968
dc.identifier.issn16806905
dc.identifier.otherhttps://doi.org/10.4314/ahs.v19i1.14
dc.identifier.otherPubMedID31148968
dc.identifier.urihttps://t.ly/BX9w7
dc.language.isoEnglishen_US
dc.publisherMakerere University, Medical Schoolen_US
dc.relation.ispartofseriesAfrican Health Sciences
dc.relation.ispartofseries19
dc.subjectChronic hepatitis cen_US
dc.subjectGenotype 4en_US
dc.subjectHepatic progenitor cellsen_US
dc.subjectResponse to therapyen_US
dc.subjectcytokeratin 19en_US
dc.subjectpeginterferon alpha2a plus ribavirinen_US
dc.subjectalpha interferonen_US
dc.subjectantivirus agenten_US
dc.subjectribavirinen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectArticleen_US
dc.subjectchronic hepatitis Cen_US
dc.subjectclinical protocolen_US
dc.subjectcontrolled studyen_US
dc.subjectcorrelation coefficienten_US
dc.subjectdemographyen_US
dc.subjectdisease activityen_US
dc.subjectdisease courseen_US
dc.subjectfatty liveren_US
dc.subjectfemaleen_US
dc.subjecthepatic progenitor cellen_US
dc.subjectHepatitis C virus genotype 4en_US
dc.subjecthumanen_US
dc.subjecthuman tissueen_US
dc.subjectimmunohistochemistryen_US
dc.subjectliver biopsyen_US
dc.subjectliver fibrosisen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmiddle ageden_US
dc.subjectoutcome assessmenten_US
dc.subjectpredictionen_US
dc.subjectprognosisen_US
dc.subjectrandomized controlled trialen_US
dc.subjectrank sum testen_US
dc.subjectretrospective studyen_US
dc.subjectyoung adulten_US
dc.subjectbiopsyen_US
dc.subjectchronic hepatitis Cen_US
dc.subjectcombination drug therapyen_US
dc.subjectdrug effecten_US
dc.subjectEgypten_US
dc.subjectgenotypeen_US
dc.subjectHepacivirusen_US
dc.subjectisolation and purificationen_US
dc.subjectliveren_US
dc.subjectpathologyen_US
dc.subjectvirologyen_US
dc.subjectAdulten_US
dc.subjectAntiviral Agentsen_US
dc.subjectBiopsyen_US
dc.subjectDrug Therapy, Combinationen_US
dc.subjectEgypten_US
dc.subjectFemaleen_US
dc.subjectGenotypeen_US
dc.subjectHepacivirusen_US
dc.subjectHepatitis C, Chronicen_US
dc.subjectHumansen_US
dc.subjectInterferon-alphaen_US
dc.subjectLiveren_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectRetrospective Studiesen_US
dc.subjectRibavirinen_US
dc.subjectYoung Adulten_US
dc.titleThe role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4en_US
dc.typeArticleen_US
dcterms.isReferencedByBruggmann, P., Berg, T., Ovrehus, A.L., Moreno, C., Branda Mello, C.E., Roudot-Thoraval, F., Historical epidemiology of hepatitis C virus (HCV) in selected countries (2014) J Viral Hepat., 21, pp. 5-33; (2012) Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012., 61, pp. 545-549. , MMWR Morbidity and Mortality Weekly Report; Feeney, E.R., Chung, R.T., Antiviral treatment of hepatitis C (2014) BMJ., 348, p. g3308; EASL recommendations on treatment of hepatitis C 2014 (2014) J. Hepatol., 61 (2), pp. 373-395; Asthana, M., Sahu, S.K., Kumar, A., Mohanty, S., Chakrabarti, S., Das, P., Role of Interleukin 28B polymorphisms in response to Interferon based therapy for hepatitis C virus clearance (2018) Curr Drug Metab.; Ragab, H.M., El Maksoud, N.A., Amin, M.A., Halim, M.H., Abdulla, N.A., Kamel, A., IL-21 as a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection (2017) Appl Biochem and Biotech.; Fried, M.W., Side effects of therapy of hepatitis C and their management (2002) Hepatology., 36, pp. S237-S244. , Nov; Sargolzaee Aval, F., Behnaz, N., Raoufy, M.R., Alavian, S.M., Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network (2014) Hepat Mon., 14 (6), p. e17028. , Jun 1; Marciano, S., Borzi, S.M., Dirchwolf, M., Ridruejo, E., Mendizabal, M., Bessone, F., Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3 (2015) World J Hepatol., 7 (4), pp. 703-709. , Apr 8; Rizk, H.H., Hamdy, N.M., Al-Ansari, N.L., Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4 (2016) PLoS One., 11 (4), p. e0153895. , Apr 21; G�nal, O., Barut, H.S.U.E., The markers predicting response to Hepatitis C virus treatment and evaluation of treatment responses (2012) J Microbiol Infec Dis., 2, pp. 100-108; El-Araby, H.A., Ehsan, N.A., Konsowa, H.A., Abd-Elaati, B.M., Sira, A.M., Hepatic progenitor cells in children with chronic hepatitis C: Correlation with histopathology, viremia, and treatment response (2015) Eur J Gastrentrol & Hepatol., 27 (5), pp. 561-569. , May; Younossi, Z.M., Birerdinc, A., Estep, M., Stepanova, M., Afendy, A., Baranova, A., The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin (2012) J Transl Med., 10, p. 25; Youssef, S.S., Abbas, E.A., Abd El Aal, A.M., Omran, M.H., Barakat, A., Seif, S.M., IL28B rs 12979860 predicts response to treatment in Egyptian hepatitis C virus genotype 4 patients and alpha fetoprotein increases its predictive strength (2014) J Interferon Cytokine Res., 34 (7), pp. 505-509. , Jul; Aref, A.M., Othman, M.S., Mamdouh, S., Dabaa, E., Hassanein, M., Saber, M.A., New biomarkers for response to treatment of HCV infected patients based on IP-10and IL 28B polymorphism analysis (2016) Am J Biochem., 6, pp. 122-129; Farber, E., Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylamino-fluorene, and 3'-methyl-4-dimethylaminoazobenzene (1956) Cancer Res., 16 (2), pp. 142-148; Tsamandas, A.C., Syrokosta, I., Thomopoulos, K., Zolota, V., Dimitropoulou, D., Liava, A., Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: A clinicopathologic study (2006) Liver Int., 26 (7), pp. 817-826. , Sep; Noritake, H., Kobayashi, Y., Ooba, Y., Matsunaga, E., Ohta, K., Shimoyama, S., Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C (2015) J Interferon & Cytokine Res., 35 (12), pp. 956-962; Derbala, M., Amer, A., Bener, A., Lopez, A.C., Omar, M., El Ghannam, M., Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis (2005) J Viral Hepat., 12 (4), pp. 380-385; El Naghi, S., Abdel-Ghaffar, T.Y., El-Karaksy, H., Abdel-Aty, E.F., El-Raziky, M.S., Allam, A.A., Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children (2014) World J Gastroenterol., 20 (16), pp. 4681-4691; Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group (1994) Hepatology., 20, pp. 15-20; Gadd, V.L., Melino, M., Roy, S., Horsfall, L., O�Rourke, P., Williams, M.R., Portal, but not lobular, macrophages express matrix metalloproteinase-9: Association with theductular reaction and fibrosis in chronic hepatitis C (2013) Liver Int., 33 (4), pp. 569-579; Tan, J., Hytiroglou, P., Wieczorek, R., Park, Y.N., Thung, S.N., Arias, B., Immunohistochemical evidence for hepatic progenitor cells in liver diseases (2002) Liver., 22 (5), pp. 365-373; Hsu, S.M., Raine, L., Fanger, H., (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures, 29 (4), pp. 577-580; Roskams, T.A., Theise, N.D., Balabaud, C., Bhagat, G., Bhathal, P.S., Bioulac-Sage, P., Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers (2004) Hepatology., 39 (6), pp. 1739-1745; Hayes, C.N., Imamura, M., Aikata, H., Chayama, K., Genetics of IL28B and HCV--response to infection and treatment (2012) Nat Rev Gastroenterol & Hepatolo., 9 (7), pp. 406-417; Al Ashgar, H., Helmy, A., Khan, M.Q., Al Kahtani, K., Al Quaiz, M., Rezeig, M., Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4 (2009) Ann Saudi Med., 29 (1), pp. 4-14; Antonucci, G., Angeletti, C., Vairo, F., Longo, M.A., Girardi, E., Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels (2009) J infect dis., 200 (9), pp. 1484-1485; Namazee, N., Sali, S., Asadi, S., Shafiei, M., Behnava, B., Alavian, S.M., Real response to therapy in chronic hepatitis C virus patients: A study from iran (2012) Hep Mon., 12 (9), p. e6151; Alavian, S.M., Tabatabaei, S.V., Keshvari, M., Behnava, B., Miri, S.M., Elizee, P.K., Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: A single-centre study of 367 cases (2010) Liver Int., 30 (8), pp. 1173-1180; Khairy, M., Fouad, R., Mabrouk, M., El-Akel, W., Awad, A.B., Salama, R., The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis (2013) Hep Mon., 13 (7), p. e10509; Jang, J.Y., Chung, R.T., Chronic hepatitis C (2011) Gut and Liver., 5 (2), pp. 117-132; D�Ambrosio, R., Aghemo, A., Rumi, M.G., Ronchi, G., Donato, M.F., Paradis, V., A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis (2012) Hepatology., 56 (2), pp. 532-543; Marshall, A., Rushbrook, S., Davies, S.E., Morris, L.S., Scott, I.S., Vowler, S.L., Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection (2005) Gastroenterology., 128 (1), pp. 33-42; Roskams, T., Yang, S.Q., Koteish, A., Durnez, A., DeVos, R., Huang, X., Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease (2003) Am J Pathol., 163 (4), pp. 1301-1311; Helal, T., Ehsan, N.A., Radwan, N.A., Abdelsameea, E., Relationship between hepatic progenitor cells and stellate cells in chronic hepatitis C genotype 4 (2018) APMIS., 126 (1), pp. 14-20; Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G., Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data (2006) Gastroenterology., 130 (6), pp. 1636-1642; Mishra, L., Banker, T., Murray, J., Byers, S., Thenappan, A., He, A.R., Liver stem cells and hepatocellular carcinoma (2009) Hepatology., 49 (1), pp. 318-329; Clouston, A.D., Powell, E.E., Walsh, M.J., Richardson, M.M., Demetris, A.J., Jonsson, J.R., Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis (2005) Hepatology., 41 (4), pp. 809-818
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download
Thumbnail Image
Name:
185658-Article Text-472078-1-10-20190417.pdf
Size:
573.79 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Faculty of Biotechnology Research Paper